FDA approves Marathon Pharmaceuticals DMD drug

(Reuters) - The U.S. Food and Drug Administration on Thursday approved Marathon Pharmaceuticals' Duchenne muscular dystrophy (DMD) drug, Emflaza, to treat patients aged 5 years and above.